title: [Angiogenesis research--quo vadis?].
abstract: The field of angiogenesis research has seen an explosion of knowledge within the last 10 years. More than 3500 angiogenesis-related papers are presently being published per year compared to the less than 200 annual papers published in the early 1990s. Paralleling the progress in the field of basic angiogenesis research, translational research has led to the identification of more than 100 angiomanipulatory compounds. Presently, more than 40 substances are in various phases of clinical trials. The prospect of these exciting developments is presently dampened by the negative outcome of some advanced clinical trials. Thus, following euphoria and disillusion, the field is presently experiencing that translational clinical research requires endurance to eventually accomplish the successful implementation of angiomanipulatory therapies in the clinical setting. The present article provides an overview of the field of angiogenesis research and summarizes ongoing efforts aimed at developing angiomanipulatory therapies.
authors.affiliation: Abt. für Vaskläre Biologie und Angiogeneseforshcung, Klinik für Tumorbiologie Freiburg. augustin@angiogenese.de
authors.forename: H G
authors.initials: HG
authors.lastname: Augustin
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000502:physiology / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017209:Apoptosis; D000068258:Bevacizumab; D002450:Cell Communication; D004353:Drug Evaluation, Preclinical; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000276:immunology; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism / Q000502:physiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D036342:Ephrins / Q000627:therapeutic use; D005544:Forecasting; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000276:immunology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D018919:Neovascularization, Physiologic / Q000502:physiology*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D012106:Research; D015398:Signal Transduction; D013792:Thalidomide / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D036342:Ephrins; D006133:Growth Substances; D006877:Hydroxamic Acids; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D013876:Thiophenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; D010649:Phenylalanine; D013792:Thalidomide; C080985:batimastat; C100342:marimastat; D040262:Receptors, Vascular Endothelial Growth Factor; D008666:Metalloendopeptidases